Alirocumab Treatment and Achievement of Non‐High‐Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

BackgroundNon‐high‐density lipoprotein cholesterol (non‐HDL‐C) and apolipoprotein (apo) B are better predictors of atherosclerotic cardiovascular disease risk than low‐density lipoprotein cholesterol alone. US and European lipid management guidelines support non‐HDL‐C and apoB as targets for lipid‐l...

Descripció completa

Dades bibliogràfiques

Autors principals:	Harold E. Bays, Lawrence A. Leiter, Helen M. Colhoun, Desmond Thompson, Laurence Bessac, Robert Pordy, Peter P. Toth
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2017-08-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	alirocumab apolipoprotein B cholesterol‐lowering hypercholesterolemia non‐high‐density lipoprotein cholesterol PCSK9
Accés en línia:	https://www.ahajournals.org/doi/10.1161/JAHA.117.005639
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!